featured
Autologous Stem Cell Transplantation After Anti–PD-1 Therapy for Multiply Relapsed or Refractory Hodgkin Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Autologous Stem Cell Transplantation After Anti-PD-1 Therapy for Multiply Relapsed or Refractory Hodgkin Lymphoma
Blood Adv 2021 Mar 23;5(6)1648-1659, RW Merryman, RA Redd, T Nishihori, J Chavez, Y Nieto, JM Darrah, U Rao, MT Byrne, DA Bond, KJ Maddocks, MA Spinner, RH Advani, HJ Ballard, J Svoboda, AK Singh, JP McGuirk, D Modi, R Ramchandren, J Romancik, JB Cohen, MJ Frigault, YB Chen, AV Serritella, J Kline, S Ansell, S Nathan, M Rahimian, RM Joyce, M Shah, KA David, S Park, AW Beaven, A Habib, V Bachanova, S Nakhoda, N Khan, RC Lynch, SD Smith, VT Ho, A LaCasce, P Armand, AF HerreraFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.